Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Oct;32(5):519-521.
doi: 10.1007/s40259-018-0297-y.

Comment on "The End of Phase 3 Clinical Trials in Biosimilars Development?"

Christopher J Webster  1 , Gillian R Woollett  2
Affiliations
Comment

Comment on "The End of Phase 3 Clinical Trials in Biosimilars Development?"

Christopher J Webster et al. BioDrugs. 2018 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

C. J. Webster consulted for Sandoz US Inc. for a single mock FDA Advisory Committee for a single biosimilar product during 2017. G. R. Woollett has no conflicts of interest.

Comment in

Comment on

References

    1. Frapaise F-X. The end of phase 3 clinical trials in biosimilars development? BioDrugs. 2018;32(4):319–324. doi: 10.1007/s40259-018-0287-0. - DOI - PubMed
    1. Biopharmaceutical industry-sponsored clinical trials: impact on state economies. Pharmaceutical Research and Manufacturers of America (PhRMA); 2015. http://phrma-docs.phrma.org/sites/default/files/pdf/biopharmaceutical-in.... Cited cost has been increased by 5% to account for real increase since publication of the report. Accessed 1 Aug 2018.
    1. Sertkaya A, Birkenbach A, Berlind A, Eyraud J; Eastern Research Group, Inc. Examination of clinical trial costs and barriers for drug development. https://aspe.hhs.gov/report/examination-clinical-trial-costs-and-barrier.... Accessed 1 Aug 2018.
    1. ICH E6 guideline for good clinical practice: a trial should be initiated and continued only if the anticipated benefits justify the risks. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Eff.... Accessed 1 Aug 2018.
    1. Vezér B, Buzás Z, Sebeszta M, Zrubka Z. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Curr Med Res Opin. 2016 doi: 10.1185/03007995.2016.1145579. - DOI - PubMed

Substances

LinkOut - more resources